Psoriasis Biosimilars Market Expected to Achieve 11.1% CAGR by 2029: Growth Forecast Insights

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

How Large Will the Psoriasis Biosimilars Market Size By 2025?
In recent times, the psoriasis biosimilars market has seen robust growth. It is set to expand from a worth of $7.32 billion in 2024 to $8.16 billion in 2025, translating to a compound annual growth rate (CAGR) of 11.5%. The surge in expansion during the historical period is related to various factors such as the escalating costs associated with original biologics, successful clinical trials, and safety data of early entrants. Other contributing factors include the expanding usage beyond psoriasis, rising prevalence of chronic diseases, and amendments in hospital procurement policies.

How Big Is the Psoriasis Biosimilars Market Size Expected to Grow by 2029?
Anticipated to witness swift expansion in the approaching years, the psoriasis biosimilars market is projected to surge to $12.43 billion by 2029, growing at a compound annual growth rate (CAGR) of 11.1%. The escalation during the prediction period is attributable to rising cases of psoriasis globally, coupled with alterations in policies and laws on interchangeability, development in biosimilar production, enhanced comprehension among patients and practitioners, and collective pricing along with contracts based on value. Key trends throughout this projection period are novel biosimilar production platforms, stratification of patients powered by artificial intelligence, the unveiling of high-tech drug dispensing devices, the creation of next-gen formulations, and calculated collaborations within the industry.

View the full report here:
https://www.thebusinessresearchcompany.com/report/psoriasis-biosimilars-global-market-report

Which Key Market Drivers Powering Psoriasis Biosimilars Market Expansion and Growth?
The growth of the psoriasis biosimilars market is anticipated to be driven by the escalating rates of psoriatic arthritis diagnosis. Psoriatic arthritis, a chronic autoimmune condition, leads to inflammation of joints and skin, frequently affecting people with a history of psoriasis. Increased psoriatic arthritis diagnosis rates are consequent to advanced screening procedures among psoriasis patients, which assist in earlier and more accurate detection by recognizing minor joint symptoms that were undetected in the past. Psoriasis biosimilars contribute to the effective management of psoriatic arthritis by offering cost-effective alternatives to biologic therapies, thereby successfully reducing joint inflammation and skin symptoms. For example, as reported by the National Institutes of Health (NIH), a US government agency, in May 2024, in 2022, the prevalence of psoriatic arthritis (PsA) was 0.221%, and the incidence rate was 13.54 per 100,000 people. As a result, the escalating diagnosis rates for psoriatic arthritis are fueling the growth of the psoriasis biosimilars market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=27399&type=smp

What Are the Key Trends Driving Psoriasis Biosimilars Market Growth?
Firms at the forefront of the psoriasis biosimilars industry are honing in on developing innovative measures, such as biosimilars for plaque psoriasis. These are designed to improve treatment availability, decrease healthcare expenses, and enhance patient results. Biosimilars for plaque psoriasis are cheaper but very similar substitutes for established biologic drugs used to manage the chronic autoimmune dermatological disorder characterized by red, flaky patches. For example, the Sandoz Group AG, a Swiss enterprise primarily involved in the generic pharmaceuticals and biosimilars sector, in May 2025, launched the Pyzchiva autoinjector, the pioneer commercially available ustekinumab biosimilar autoinjector. Pyzchiva is sanctioned for treating adults with plaque psoriasis, psoriatic arthritis, and Crohn's disease, as well as children from six years of age (weighing more than 60 kg) with plaque psoriasis. The autoinjector, built to boost patient compliance and lifestyle quality, boasts accurate automated dosing, lessened injection-related pain, a compact build, and adaptable storage selections for easier self-administration.

What Are the Emerging Segments in the Psoriasis Biosimilars Market?
The psoriasis biosimilars market covered in this report is segmented

1) By Drug Class: TNF-Alpha Inhibitors, Infliximab, Etanercept, Adalimumab, Other Biosimilars
2) By Disease Type: Plaque Psoriasis, Guttate Psoriasis, Inverse Psoriasis, Pustular Psoriasis
3) By Route Of Administration: Subcutaneous, Intravenous, Oral, Topical
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:
1) By TNF-Alpha Inhibitors: Monoclonal Antibody Biosimilars, Fusion Protein Biosimilars
2) By Infliximab: Remicade Biosimilars, CT-P13 Biosimilars
3) By Etanercept: Enbrel Biosimilars, SB4 Biosimilars
4) By Adalimumab: Humira Biosimilars, ABP 501 Biosimilars
5) By Other Biosimilars: Ustekinumab Biosimilars, Secukinumab Biosimilars

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=27399&type=smp

Who Are the Global Leaders in the Psoriasis Biosimilars Market?
Major companies operating in the psoriasis biosimilars market are Pfizer Inc., Merck & Co. Inc., Amgen Inc., Biogen Inc., Sandoz Group AG, Fresenius Kabi AG, Intas Pharmaceuticals Ltd., STADA Arzneimittel AG, Aurobindo Pharma Ltd., Dr. Reddy's Laboratories Ltd., Cipla Ltd., Samsung Bioepis Co. Ltd., Lupin Ltd., Zydus Lifesciences Ltd., Celltrion Inc., Torrent Pharmaceuticals Ltd., Bio-Thera Solutions Ltd., Coherus BioSciences Inc., mAbxience S.A., Reliance Life Sciences Pvt. Ltd., and Alvotech hf.

Which are the Top Profitable Regional Markets for the Psoriasis Biosimilars Industry?
North America was the largest region in the psoriasis biosimilars market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the psoriasis biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=27399

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.